Purple Biotech to Showcase CAPTN-3 Platform at EACR 2025 Congress
ByAinvest
Wednesday, Jun 4, 2025 1:53 pm ET1min read
PPBT--
The abstract, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, Vice President of Research and Development at Purple Biotech. The abstract will be available online following the presentation [1].
Purple Biotech focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a novel target for multiple cancer indications. NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [1].
The CAPTN-3 platform is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response [1].
The company's corporate headquarters are located in Rehovot, Israel. For more information, please visit the official website of Purple Biotech [1].
References:
[1] https://www.globenewswire.com/news-release/2025/06/04/3093432/0/en/Purple-Biotech-Announces-Poster-Presentation-at-EACR-2025-on-its-Novel-CAPTN-3-Tri-Specific-Antibody-Platform.html
Purple Biotech will present a poster on its CAPTN-3 tri-specific antibody platform at EACR 2025. The presentation is scheduled for June 17, 2025, during the Immunotherapy session in Lisbon, Portugal. The abstract will be published online post-presentation. Purple Biotech is a clinical-stage biopharmaceutical company focusing on overcoming tumor immune evasion and drug resistance through its developmental therapies.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company, has announced that it will present a poster on its novel CAPTN-3 tri-specific antibody platform at the European Association for Cancer Research (EACR) 2025. The presentation is scheduled for June 17, 2025, during the Immunotherapy session in Lisbon, Portugal.The abstract, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, Vice President of Research and Development at Purple Biotech. The abstract will be available online following the presentation [1].
Purple Biotech focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a novel target for multiple cancer indications. NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [1].
The CAPTN-3 platform is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response [1].
The company's corporate headquarters are located in Rehovot, Israel. For more information, please visit the official website of Purple Biotech [1].
References:
[1] https://www.globenewswire.com/news-release/2025/06/04/3093432/0/en/Purple-Biotech-Announces-Poster-Presentation-at-EACR-2025-on-its-Novel-CAPTN-3-Tri-Specific-Antibody-Platform.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet